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Non-steroidal anti-inflammatory drugs (NSAIDs) are at the cornerstone of treatment for 
osteoarthritis (OA). In recent years, the widespread use of oral NSAIDs has been called into 
question due to the appearance of significant upper gastrointestinal (GI) complications and 
cardiovascular (CV) adverse events (AEs). However, NSAIDs are non-homogeneous, and 
there are noticeable differences between them in AE risk for GI and CV events. 
Nevertheless, if properly prescribed oral NSAIDs can provide an effective and safe treatment 
for OA in real-life situations. The identification of patients with significant CV and/or GI risk is 
critical, and the European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) treatment algorithm provides guidance on appropriate treatments for 
OA patients with elevated risk. Among non-selective NSAIDs, ibuprofen and naproxen seem 
preferable to diclofenac, the latter being associated with higher CV risk. Recommendation 
has been made by some that naproxen may be the preferred agent in patients at high CV 
risk because of its lower risk of CV events. Low dose celecoxib (200 mg/day) is also 
associated with a lower risk of CV events compared with other coxibs. In addition, drugs with 
a demonstrated low GI risk profile may be of benefit, such as coxibs and nabumetone. 
Among patients who fail to respond adequately to sequential ESCEO algorithm Step 1 and 
Step 2 treatments, the short-term use of weak opioids, such as tramadol, for severely 
symptomatic OA patients is recommended. Although studies exploring the efficacy of 
tramadol in OA are limited, there is good evidence that tramadol works if prescribed 
properly. The sustained-release (SR) formulation of tramadol is preferred as it avoids the 
peak plasma concentrations reached with immediate-release tramadol, which is believed to 
reduce the incidence of AEs. Furthermore, slow upwards titration of tramadol SR is 






The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 
(ESCEO) treatment algorithm recommends oral non-steroidal anti-inflammatory drugs 
(NSAIDs) for Step 2 advanced pharmacological management of knee osteoarthritis (OA) if 
Step 1 treatment shows inadequate efficacy and the patient is still symptomatic, or in 
patients presenting with moderate-severe pain (1). Oral NSAIDs are universally 
recommended across the international and national guidelines (see Table 1) in patients with 
persistent symptoms that have not responded adequately to paracetamol with or without 
topical NSAIDs or, in the ESCEO recommendations, to symptomatic slow-acting drugs for 
osteoarthritis (SYSADOAs) (1-5). Oral NSAIDs have a moderate effect on pain relief, with an 
effect size (ES) of 0.29 (95% confidence interval [CI] 0.22 to 0.35) that is greater than that of 
paracetamol (ES = 0.14; 95% CI 0.05 to 0.22) (6). Use of oral NSAIDs has been associated 
with greater efficacy in patients with more severe knee and hip OA accompanied by a higher 
degree of patient preference compared with paracetamol (7). Cyclo-oxygenase-2 (COX-2) 
selective, partially-selective, or non-selective oral NSAIDs are similarly effective in controlling 
pain (8). Thus, drug choice is dictated by their safety profile, according to different risk 
factors, and patients’ concomitant diseases and medical conditions (1). 
Table 1 Recommendations for the use of oral non-steroidal anti-inflammatory drugs 
(NSAIDs) for osteoarthritis. 
Guideline committee OA 
location 
Recommendation for oral NSAIDs 
European Society for Clinical and 
Economic Aspects of Osteoporosis 
and Osteoarthritis (ESCEO) 
Knee Recommended when paracetamol or 
SYSADOAs and/or topical NSAIDs are 
not adequately effective 
European League Against 
Rheumatism (EULAR) 
Knee Consider in patients unresponsive to 
paracetamol 




Conditionally recommended for initial 
therapy; strongly recommended in knee 
OA patients unresponsive to 
paracetamol 
Osteoarthritis Research Society 
International (OARSI) 
Knee Appropriate for individuals without 
relevant co-morbidities; uncertain for 
those with moderate co-morbidity risk 
National Institute for Health and 
Care Excellence (NICE) 
Hand, 
knee, hip 
Use when paracetamol and/or topical 
NSAIDs are ineffective, or in addition to 
paracetamol or topical NSAIDs when 
insufficient pain relief is achieved  
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Table 1 abbreviations: OA, osteoarthritis; NSAIDs, non-steroidal anti-inflammatory drugs; 
SYSADOAs, symptomatic slow-acting drugs for osteoarthritis. 
 
Among patients who fail to respond adequately to sequential Step 1 and Step 2 treatments, 
the ESCEO algorithm recommends the short-term use of weak opioids, such as tramadol, as 
a last pharmacological treatment before recourse to surgery (1). Similarly, the American 
College of Rheumatology (ACR) recommends tramadol as an appropriate analgesic in OA 
pain when non-opioid analgesics, coxibs, and non-selective NSAIDs are poorly tolerated, 
ineffective, or contraindicated (3). The antidepressant duloxetine is also proposed by the 
ESCEO at Stage 3 in treatment (1); however, the combination of tramadol and duloxetine is 
not recommended due to their similar central mechanism of action.  
 
2.0 Examination of the evidence base for oral NSAID safety 
The NSAIDs are non-homogeneous as a drug class, and there are vast differences between 
individual drugs in terms of adverse event (AE) risk for gastrointestinal (GI) and 
cardiovascular (CV) complications. Thus, the benefit-risk balance of individual NSAIDs is 
mainly driven by their GI and CV safety profile. The US Food and Drug Administration (FDA) 
has issued a ‘black box’ safety warning for the entire oral NSAID drug class highlighting the 
potential for increased risk of CV events and GI bleeding associated with their use (9).  
 
2.1 Upper GI complications 
Oral NSAID treatment is associated with a 3- to 5-fold increase in the risk of upper GI 
complications (UGIC), including peptic ulcer perforation, obstruction and bleeding (10, 11). 
GI side effects from NSAIDs arise from both topical injury and COX-1 inhibition, which is 
present even when a parenteral formulation is used, and data indicate a similar safety and 
tolerability profile with intravenous and oral ibuprofen, for example (12). While COX-2 
selective agents are associated with fewer GI ulcer complications, there is still an increased 
risk of UGIC (13). Systematic review and meta-analyses have identified considerable 
variability in the risk of UGIC among individual oral NSAIDs as used in clinical practice (13, 
14). Piroxicam, ketorolac and azapropazone were associated with the highest relative risk of 
UGIC, while aceclofenac, celecoxib and ibuprofen were associated with the lowest relative 
risk, and an intermediate level of risk was found for all other NSAIDs included in the review 
(Figure 1) (13). The high risk of UGIC with indomethacin may be attenuated by use of 
acemetacin, a pro-drug for indomethacin. Acemetacin is less active on the COX-1 enzyme in 
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the gastric mucosa, and was found in one study to exhibit similar efficacy in OA with around 
one-third the incidence of GI AEs found with indomethacin (15). Acemetacin was also 
demonstrated to have similar efficacy and safety to celecoxib in knee OA treatment over 6 
weeks (16). Nabumetone is an NSAID that exhibits equivalent efficacy to many others but 
with a comparatively good safety profile (17), with 10-fold fewer GI AEs (perforations, ulcers 
or bleedings) reported across clinical studies compared with other NSAIDs (18, 19).  
High daily doses of several NSAIDs are associated with a 2- to 3-fold increase in the relative 
risk of UGIC compared with low-medium doses, with the exception of celecoxib for which no 
dose-response relationship was found (13). These findings provide a strong rationale for the 
use, whenever possible, of low drug dosages for the shorter period of time to minimize GI 
toxicity. 
 
Figure 1 Pooled relative risks and 95% confidence intervals of upper gastrointestinal 
complications associated with the use of individual NSAIDs (13). Vertical bars denote 95% 
CIs. 
 
<Figure 1 taken from Castellague 2012 (13); Reproduction granted under Creative 





2.2 CV complications 
The association of NSAIDs with increased CV risk is a complex issue, but there is today little 
doubt that all oral NSAIDs, selective and non-selective, have the potential to increase the 
risk of serious CV events. The coxib and traditional NSAID trialists (CNT) collaboration 
performed a meta-analysis of 639 RCTs, and found that major vascular events were 
increased by about a third with a coxib (rate ratio [RR] 1.37; 95% CI 1.14 to 1.66; p=0.0009) 
or diclofenac (150 mg/day) (RR 1.41; 95% CI 1.12 to 1.78; p=0.0036) compared with 
placebo (Figure 2) (20). This was largely due to an increase of around three-quarters in the 
risk of major coronary events. Ibuprofen (2400/day) also significantly increased major 
coronary events (RR 2.22; 95% CI 1.10 to 4.48; p=0.0253) but not major vascular events 
(RR 1.44; 95% CI 0.89 to 2.33; p=0.14). In contrast, high dose naproxen (1000 mg/day) was 
associated with less vascular risk than other NSAIDs (RR 0.93; 95% CI 0.69 to 1.27; p=0.66) 
and no increase in major coronary events (RR 0.84; 95% CI 0.52 to 1.35; p=0.48) (20). 
There was no evidence that any NSAID significantly increased the risk of stroke, although an 
earlier network meta-analysis had found a higher risk of stroke with ibuprofen (RR 3.36; 95% 
CI 1.00 to 11.6) (21). While the vascular risks of different coxib regimens appeared similar at 
the most frequently studied daily doses, there was a trend for lower risk with lower celecoxib 
doses; although the vascular effects of the most widely used coxib regimen, celecoxib 200 
mg/day, were statistically uncertain (20). Vascular risk is likely related to the degree of COX-
2 inhibition, which increases with dose, suggesting a dose-dependent effect.  
Figure 2 Effects of coxib and traditional NSAID treatment on risk of major vascular events 
(20). 
 
Major vascular events includes: non-fatal myocardial infarction (MI), coronary death, MI or 
coronary heart disease, non-fatal stroke, stroke death, any stroke, other vascular death. 
CI, confidence interval; RR, rate ratio. 




The risk of acute myocardial infarction (MI) with individual coxibs and non-selective oral 
NSAIDs was also previously assessed in a large nested case-control study that included 
over 2,356,885 person-years of follow-up and 15,343 cases of acute MI (22). Indomethacin, 
sulindac, and meloxicam were associated with the highest increased risk of acute MI, while 
nabumetone was associated with the lowest risk of acute MI (Figure 3). Among the coxibs, 
rofecoxib was associated with the highest risk, while celecoxib (all dosages) and low dose 
valdecoxib (20 mg/day) were associated with the lowest risk of acute MI (22).  
 
Figure 3 Risk for acute myocardial infarction with non-selective NSAIDs and COX-2 
inhibitors (22). 
 
<Figure 3 adapted from Singh EULAR 2005 (22)> 
 
3.0 Guidance on use of NSAIDs in real-life OA patients 
The choice of NSAID to use in clinical practice depends on individual patient characteristics 
and medical history. Several patient factors have been identified to increase the risk of 
UGIC, including advanced age, a history of GI ulcer, and concomitant treatment with 
corticosteroids, aspirin or anticoagulants (Figure 4) (23, 24). The ESCEO recommends that 
patients are assessed for risk factors and the risk:benefit ratio of treatment is determined 
before making treatment decisions. Patient preference is an important consideration, for 
example, of dosing regimen whether once-daily or more frequent dosing is desirable.  












Odds ratio (OR) for acute myocardial infarction (95% CI)
OR 95% CI p
1.71 1.35-2.17 0.0001
1.41 1.01-1.96 < 0.04
1.37 1.05-1.78 < 0.02
1.32 1.22-1.42 < 0.0001
1.11 1.01-1.22 < 0.02

















<Figure 4 Adapted from Hunt 2002 (24)> 
 
GI complications associated with oral NSAID use are the most common serious adverse 
drug reactions in the US. A large majority of NSAID-associated GI adverse events (AEs) are 
asymptomatic until a complication occurs, i.e. they are not preceded by mild side effects 
such as abdominal pain and vomiting (25). The use of concomitant gastroprotective agents 
such as proton pump inhibitors (PPIs) are the most commonly recommended treatments to 
reduce the risk of GI complications with non-selective NSAIDs. Moreover, concomitant use 
of high dose of famotidine or misoprostol can also reduce the occurrence of gastric ulcer 
complications by 50–60% (26). Among patients with a prior history of ulcer bleeding, 
treatment with diclofenac plus omeprazole was shown to be as safe as treatment with 
celecoxib, with respect to the prevention of recurrent bleeding (27).  
While coxibs are associated with a lower risk of UGIC compared with non-selective NSAIDs, 
there is still a significant increase in risk compared with placebo (20). The ESCEO algorithm 
recommends that in patients with low (normal) GI risk, it should be considered to prescribe 
either a non-selective NSAID with or without a PPI or a COX-2 selective NSAID, based on 
the judgment of the clinicians. In patients with high GI risk, which includes patients receiving 
concomitant low-dose aspirin, non-selective NSAIDs should be avoided and COX-2 selective 














Relative risk of GI gastropathy in men
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Table 2 ESCEO recommendations for Step 2 advanced pharmacological management of 
persistent symptoms in patients with osteoarthritis using oral NSAIDs (1). 
Intermittent or continuous (longer cycles) oral NSAIDs 
Normal GI risk Increased GI risk* Increased CV risk Increased renal risk 
• Non-selective 
NSAID with PPI 
• COX-2 selective 
NSAID (consider 
PPI) 
• COX-2 selective 
NSAID with PPI 
• Avoid non-
selective NSAIDs 
• Prefer naproxen 
• Avoid high-dose 
diclofenac and 
ibuprofen (if on low-
dose aspirin) 
• Caution with other 
non-selective 
NSAIDs 
• Avoid COX-2 
selective NSAIDs 
• Avoid NSAIDs† 
*Including use of low-dose aspirin; †with glomerular filtration rate <30 cc/min, caution in other 
cases; COX-2, cyclooxygenase-2; CV, cardiovascular; GI, gastrointestinal; NSAID, non-
steroidal anti-inflammatory drug; PPI, proton pump inhibitor. 
<Table 2 adapted from Bruyere 2014 (1)> 
 
Regarding CV risk associated with oral NSAID use, early evidence suggested that the 
relative risk of CV events increased with increased baseline CV risk (29); although a recent 
and comprehensive meta-analysis found that the proportional increase in risk was similar 
irrespective of baseline risk (20). Thus, these drugs should be avoided in high CV risk 
patients and probably other non-selective NSAIDs as well. Ibuprofen should not be used with 
concomitant low-dose aspirin due to clinically relevant pharmacological interaction (30). 
Naproxen is the exception, and may be the preferred agent if an NSAID is required in 
patients at high CV risk, because of its lower risk of CV events (20, 31). The lower risk of CV 
thrombovascular events associated with naproxen may be due to its sustained suppression 
of platelet aggregation (20). In a 2012 report, the European Medicines Agency (EMA) stated 
that naproxen may be associated with a lower risk of arterial thrombotic events than COX-2 
inhibitors and other NSAIDs (32). In addition, following a review of CV safety, the EMA 
issued a warning for oral diclofenac treatment not to be prescribed to patients with ischemic 
heart disease, peripheral arterial disease, cerebrovascular disease, or established 
congestive heart failure, which was subsequently endorsed by the European Commission 
(33). The ESCEO and ACR recommend that oral NSAID use is avoided in patients with 
increased renal risk, such as chronic kidney disease with estimated glomerular filtration rate 
below 30 cc/min (1, 3).  
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Due to the risk of GI and CV events, the product information for all NSAIDs recommends 
that these medicines be used at the lowest effective dose for the shortest period of time 
necessary to control symptoms (32). The ESCEO algorithm recommends that oral NSAIDs 
may be used intermittently or continuously in longer cycles rather than in chronic use, 
because of safety concerns and a lack of long-term trials (1). A recent short-term trial of low-
dose celecoxib (200 mg/day) found that continuous treatment with celecoxib over 22 weeks 
was significantly more effective than intermittent use in preventing OA flares of the hip and 
knee without an increase in overall AEs including GI disorders and hypertension (34). 
However, the select population included in the trial has low risk CV and GI risks and, 
therefore, is not representative of the general OA patient population.  
In the event of insufficient control of symptoms with an NSAID, the combination of NSAIDs is 
not recommended by the ESCEO task force, as there is no evidence of additional benefit, 
and an increased risk of AEs, with additional cost of treatment. While switching NSAIDs may 
provide some benefit, the ESCEO task force does not recommend multiple successive 
rounds of NSAIDs before considering other treatment options. If the patient is still 
symptomatic despite use of NSAIDs, the ESCEO algorithm recommends intra-articular 
treatment, or recourse to short-term weak opioids, e.g. tramadol (1). 
 
4.0 Pharmacological treatment with weak opioids 
Among OA patients who fail to respond adequately to pharmacological treatments, including 
oral NSAIDs, the ESCEO algorithm recommends the short-term use of weak opioids, such 
as tramadol, as one of the last pharmacological treatments before recourse to surgery (1). 
Tramadol is a synthetic, centrally-acting analgesic with opioid agonist properties that acts on 
the neurotransmission of norepinephrine and serotonin. In addition, tramadol modifies the 
transmission of pain impulses by inhibition of monoamine reuptake. Tramadol rarely causes 
the AEs of respiratory depression and physical dependence commonly associated with 
conventional opioid drugs, since its analgesic effects are through both weak opioid and non-
opioid mechanisms (35). Tramadol is not attributed with the GI and CV AEs associated with 
NSAIDs (36). However, the use of tramadol may be impeded by non-serious AEs, 
predominantly nausea and headache, resulting in treatment withdrawal and sub-optimal pain 
management (37, 38). Sustained release (SR) formulations of tramadol may improve 
tramadol tolerability and reduce the incidence of AEs (39). SR formulations are associated 
with prolonged effective plasma levels of tramadol, while preventing the high plasma peaks 
associated with AEs seen with the immediate-release formulations (39, 40). In addition, 
multiple-unit SR capsule formulation produces a smoother and extended tramadol plasma 
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concentration profile compared with single-unit SR tablets due to a more gradual release of 
tramadol (39). Further, the slow upward titration of SR tramadol is recommended to minimize 
AEs and premature treatment discontinuations (41). The dose titration of multiple-unit SR 
tramadol leads to a reduced incidence of AEs and reduced frequency of treatment 
discontinuations (Figure 5) (41). 
 
Figure 5 Effect of dose titration of multiple-unit SR tramadol (50 to 100 mg bid, over 7 days) 
on incidence of AEs leading to treatment discontinuations. 
 
<Figure 5 Adapted from Tagarro 2005 (41)> 
 
A Cochrane review of RCTs showed that the efficacy of tramadol in relieving pain and 
improving function in knee OA is small but significant, although AEs are significantly 
increased over placebo and may lead to treatment withdrawal (36). Treating OA patients 
with short-term tramadol may decrease pain, reduce stiffness and improve function, and 
overall well-being (36). In a placebo-controlled study of tramadol in patients with OA, 
patients did significantly better with tramadol than with placebo (42). 
 
 









Tramadol SR 100 mg BID, no titration
Tramadol SR 50 mg BID, escalating to 100 mg BID after 7 days
% Patients with adverse events leading to treatment discontinuation 









NSAIDs are non-homogeneous, and there are vast differences in AE risk for GI and CV 
events. Nonetheless, if properly prescribed oral NSAIDs can provide an effective and safe 
treatment for OA. The identification of patients at risk of significant CV and/or GI side effects 
is crucial, and the ESCEO algorithm provides guidance on appropriate treatments for OA 
patients with elevated risk. Low dose celecoxib (100–200 mg/day) is associated with a lower 
risk of CV events compared with other coxibs and diclofenac. Among non-selective NSAIDs, 
ibuprofen and naproxen are preferable to diclofenac. In addition, other drugs with a 
demonstrated low risk AE profile may be of benefit such as nabumetone and acemetacin, 
which shows similar efficacy and safety to celecoxib. Intermittent cycles of treatment are 
usually preferable than continuous administration, to minimize the risk of AEs. The 
combination of NSAIDs is discouraged as this provides no additional benefit, with an 
increased risk of AEs and additional cost. Multiple successive rounds of NSAIDs should also 
be avoided in patients with persistent symptoms before considering subsequent steps in the 
ESCEO recommended treatment algorithm.  
The short-term use of soft weak opioids, such as tramadol, may be considered for severely 
symptomatic OA patients. Although studies of tramadol are limited in OA, there is good 
evidence that tramadol works if prescribed properly. The SR formulation of tramadol is 
preferred as it avoids the peak plasma concentrations, and consequently reduces the 
incidence of side effects. Furthermore, slow upwards titration of SR tramadol is 
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